Everything below concerns 白蛋白结合. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-19. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
In addition to non-viral delivery methods, RNA viruses have been engineered to achieve similar immunological responses. Typical RNA viruses used as vectors include retroviruses, lentiviruses, alphaviruses and rhabdoviruses, each of which can differ in structure and function. Clinical studies have utilized such viruses on a range of diseases in model animals such as mice, chicken and primates.
=== Response from health organizations === The American Cancer Society "has no formal position regarding rBGH". The American Nurses Association supports the development of national and state laws, regulations, and policies that specifically reduce the use of rBGH or rBST in milk and dairy production in the United States.
The oxidation step uses oxidised nicotinamide adenine dinucleotide as a cofactor and the enzyme also requires zinc. It belongs to the family of oxidoreductases, specifically those acting on single donors with O2 as oxidant and incorporation of two atoms of oxygen into the substrate (oxygenases). The oxygen incorporated need not be derived from O2. The systematic name of this enzyme class is 3,4-dihydroxy-L-phenylalanine:oxygen 4,5-oxidoreductase (recyclizing). It participates in tyrosine metabolism.
Breast augmentation (also breast enlargement) is a plastic surgery procedure by which either a breast implant or a fat-graft implant is emplaced to the thorax to increase the size of the breasts in order to correct congenital defects of the breast and of the chest wall. Consequently, after the breast-enlargement surgery, the symmetrical breast hemisphere is of proportionate size, has a smooth contour, and is anatomically consistent with the woman's body. Three therapeutic purposes require the emplacement of a prosthetic breast: (i) primary reconstruction surgery of the chest and breast tissues damaged by breast cancer, blunt trauma, penetrating trauma, and blast injury; and of developmental defects of the thoracic anatomy, e.g. the tuberous breast deformity; (ii) the surgical revision and reconstruction of chest-and-breast-tissue complications arisen from a previous mammoplasty; and (iii) primary augmentation to surgically enhance the aesthetics of the bust and the breasts. To augment the volume of the breast hemisphere, a prosthetic breast (saline or silicone) establishes the initial spherical augmentation of the breast for contouring by the plastic surgeon. To augment the volume of the breast hemisphere with autologous adipocyte tissue, the surgeon injects the woman's refined body-fat into the skin envelope to correct contour defects of the breast hemisphere. A fat-graft breast augmentation yields a breast-size increase is of modest volume, usually one brassière cup-size, consequent to the body's usual resorbtion of most of the autologous fat-graft.
Sources: en.wikipedia.org
Entourage Guimard: Square-Victoria–OACI station on the Montreal Metro in Canada has a genuine Guimard entrance made from parts of demolished Paris entrances (with map holder and "Métropolitain" sign and holder reproduced from the original molds). It was installed in 1967. During restoration in 2001–2002, it was found to have the last examples of the original glass light globes, which in Paris had been replaced with plastic for safety; one was returned to the RATP and the other placed on display in the Montreal Museum of Fine Arts. Bellas Artes station on the Mexico City Metro in Mexico has a Guimard entrance installed in 1998. Picoas station on the Lisbon Metro in Portugal has a Guimard entrance installed in 1995. Kievskaya station on the Moscow Metro in Russia has a Guimard entrance installed in 2007. Van Buren Street station on the Metra Electric District in Chicago had a Guimard entrance installed in 2001. An Entrance to the Paris Métropolitain: The National Gallery of Art in Washington, D.C., United States has a Guimard entrance in its sculpture garden, first shown at the gallery in a 2000–2001 exhibition on Art Nouveau and permanently installed in the garden in 2003. The Museum of Modern Art in New York City, United States has the archway consisting of the light stalks and "Métropolitain" sign from the Guimard entrance to Raspail station. The Dali Theater Museum in Figueres (Girona, Spain) has a pair of the light stalks from a Guimard Métro entrance, which are exhibited on the patio.
== Regulation == G6PD converts G6P into 6-phosphoglucono-δ-lactone and is the rate-limiting enzyme of the pentose phosphate pathway. Thus, regulation of G6PD has downstream consequences for the activity of the rest of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase is stimulated by its substrate G6P. The usual ratio of NADPH/NADP+ in the cytosol of tissues engaged in biosyntheses is about 100/1. Increased utilization of NADPH for fatty acid biosynthesis will dramatically increase the level of NADP+, thus stimulating G6PD to produce more NADPH. Yeast G6PD is inhibited by long chain fatty acids according to two older publications and might be product inhibition in fatty acid synthesis which requires NADPH. G6PD is negatively regulated by acetylation on lysine 403 (Lys403), an evolutionarily conserved residue. The K403 acetylated G6PD is incapable of forming active dimers and displays a complete loss of activity. Mechanistically, acetylating Lys403 sterically hinders the NADP+ from entering the NADP+ structural site, which reduces the stability of the enzyme. Cells sense extracellular oxidative stimuli to decrease G6PD acetylation in a SIRT2-dependent manner. The SIRT2-mediated deacetylation and activation of G6PD stimulates pentose phosphate pathway to supply cytosolic NADPH to counteract oxidative damage and protect mouse erythrocytes. Regulation can also occur through genetic pathways. The isoform, G6PDH, is regulated by transcription and posttranscription factors.
In addition to their cytoplasmic machinery, eukaryotic mitochondria and plastids have their own translation machinery, each with their own set of bacterial-type elongation factors. In humans, they include TUFM, TSFM, GFM1, GFM2, GUF1; the nominal release factor MTRFR may also play a role in elongation. In bacteria, selenocysteinyl-tRNA requires a special elongation factor SelB (P14081) related to EF-Tu. A few homologs are also found in archaea, but the functions are unknown.
Sources: en.wikipedia.org
Duncan returns to the mansion, where the few remaining henchmen flee rather than face him. Now alone, Blut awaits Duncan but ends up decapitated while calling for someone to bring him Camille. Rescuing Camille, Duncan returns to Montana and treats her inside her cabin. Duncan awakens one morning inside the cabin to find newspaper clippings of the murder of a family spread around Camille's bed. He recognizes the images as a hit that he carried out, albeit with bad intel, something that has haunted him ever since. The only survivor of the family was a daughter, who grew up to be Camille. To assuage his guilty conscience he has been making anonymous donations to her ever since, and she tracked him down by following the money trail. Held at gunpoint by Camille, Duncan apologizes and tells her to close her mind and pull the trigger. However, she spares him, asking if they can determine who ordered her father dead, and he commits to help her.
=== Vasodilation === Substance P is a potent vasodilator. Substance P–induced vasodilation is dependent on nitric oxide release. Substance P is involved in the axon reflex-mediated vasodilation to local heating and wheal and flare reaction. It has been shown that vasodilation to Substance P is dependent on the NK1 receptor located on the endothelium. In contrast to other neuropeptides studied in human skin, Substance P–induced vasodilation has been found to decline during continuous infusion. This possibly suggests an internalization of neurokinin-1 (NK1). As is typical with many vasodilators, it also has bronchoconstrictive properties, administered through the non-adrenergic, non-cholinergic nervous system (branch of the vagal system).
== Ultimate Fighting Championship (UFC) == In December 2013, the UFC began a campaign to drug test their entire roster randomly all year-round. Random testing, however, became problematic for the promotion as it began to affect revenue, as fighters who had tested positive would need to be taken out of fights, which adversely affected fight cards, and therefore pay-per-view sales. If the UFC were not able to find a replacement fighter fights would have to be cancelled. According to Steven Marrocco of MMAjunkie.com, about 31% of UFC fighters subjected to random testing since the program first started have failed due to using performance-enhancing drugs. That is approximately five failed tests for every sixteen random screenings. No fighters are exempt from these tests, no matter how big or small. Former Bantamweight champion T.J. Dillashaw tested positive for EPO following his fight with Henry Cejudo in January 2019. Jon Jones, the former Heavyweight and Light Heavyweight champion in the UFC, tested positive for banned substances in June 2016. Jones urine was found to contain Clomiphene and Letrozole which lead to a one-year suspension from the sport. Another highly decorated fighter by the name of Anderson Silva tested positive for two anabolic steroids following his bout against Nick Diaz at UFC 183. The steroids were methyltestosterone and Hydrochlorothiazide. From July 2015, the UFC has advocated to all commissions that every fighter be tested in competition for every card.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.